Finance News Network reported on November 8th that due to the severe abnormal volatility in stock trading, the STAR Market stock Haobor, which hit the limit for 7 consecutive days, will be suspended for verification, becoming the first stock recently suspended due to abnormal stock price fluctuations.

Tonight, Haobor announced that the company's stock price hit the limit for 7 consecutive trading days from October 31, 2024 to November 8, 2024, during which it repeatedly experienced abnormal and severe abnormal volatility in stock trading. The company will suspend trading for verification of the abnormal stock trading situation, and the suspension is expected to last no more than 3 trading days.

Meanwhile, the company mentioned in the relevant risk warning:

1. In accordance with the Company Law and Securities Law and other relevant laws and regulations, the company will disclose major information that may affect the company's stock price to investors in a true, accurate, timely, complete, and fair manner, for investors to make investment decisions. Due to objective constraints, the company cannot grasp the reasons and trends of the stock market changes. The company reminds investors to pay attention to stock price fluctuations and risks that may be involved in future stock markets.

2. The company is mainly engaged in the research, production, and sale of in vitro diagnostic reagents. The company's diagnostic products mainly focus on testing for various diseases in the fields of allergies and autoimmunity. From January to September 2024, the company achieved revenue of 307,033,592.46 yuan, a year-on-year increase of 2.29%; net profit attributable to shareholders of the listed company was 26,562,954.15 yuan, a year-on-year decrease of 31.24%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25,311,935.72 yuan, a year-on-year decrease of 25.87%.

3. The controlling shareholder, Hairuixiangtian, has transferred the company's shares to Brilliance Runkang. The transaction has been approved by the China Biopharmaceutical Limited Board of Directors, the actual controller of Brilliance Runkang, Shuangrunzhengan, and JOHNLi. The "Share Transfer Agreement" involved in this transaction has been internally decided and signed by the contracting parties awaits approval at the Company's shareholders' meeting for exemption of JOHNLI's voluntary share lock-up commitment and approval of the company's strategic cooperation with China Biopharmaceutical Limited, Hairuixiangtian, and JOHNLi to take effect; after the effectiveness of the "Share Transfer Agreement", compliance confirmation from the Shanghai Stock Exchange and other approvals required by relevant laws and regulations must be obtained before the share transfer registration procedures can be handled at the Shanghai Branch of China Securities Depository and Clearing Corporation Limited. There is a certain degree of uncertainty regarding whether the relevant approval procedures can be passed and the time taken, and investors are advised to pay attention to investment risks.

4. The company's initial public offering price was 35.26 yuan per share. As of November 8, 2024, the closing price of the company was 114.84 yuan per share, higher than the company's initial public offering price. According to the latest P/E ratio published by China Securities Index Co., Ltd., the company's latest P/E ratio is 153.00 times, and the latest trailing P/E ratio is 205.37 times. The average trailing P/E ratio of the pharmaceutical manufacturing industry in the past month was 26.96 times. The company's P/E ratio is significantly higher than the industry average. The company specifically reminds investors to pay attention to investment risks, make rational decisions, and invest carefully.

On the same day, Ho-Oh Bo also issued a reply to the "Inquiry Letter Regarding the Serious Abnormal Fluctuations in the Trading of Jiangsu Ho-Oh Bo Biomedical Pharmaceutical Co., Ltd. Stock". The controlling shareholder, Hairuitekangtian Biotechnology (Group) Co., Ltd., stated in the reply that as the controlling shareholder of Ho-Oh Bo, up to now, apart from the information publicly disclosed by Ho-Oh Bo in designated media, the company does not have any other significant information that may have a significant impact on the trading price of the listed company's stock but has not been disclosed, including but not limited to major matters such as planning mergers and restructurings, share issuances, debt restructurings, business restructurings, asset divestitures, and asset injections. It also clearly states that the company and persons acting in concert have not bought or sold shares of your company during the period of serious abnormal fluctuations in your company's stock trading.

In terms of stock price, Ho-Oh Bo's stock price has seen seven consecutive 20cm limit-up moves since resuming trading on October 31, with a cumulative increase of 258.3% during this period.

Previously, Ho-Oh Bo was suspended from trading due to the controlling shareholder planning changes in control rights. On October 30, Ho-Oh Bo issued a resumption announcement stating that the company's controlling shareholder, Hairuitekangtian, and persons acting in concert, Suzhou Wairun Investment Management Partnership Enterprise, the company's actual controllers JOHNLI, WEIJUNLI, Chen Tao, and Beijing Huirun Runkang Pharmaceutical Development Co., Ltd., and persons acting in concert, Shuangrunzhengan Information Consulting (Beijing) Co., Ltd., signed a "Share Transfer Agreement". On the same day, the company signed a "Strategic Cooperation Agreement" with China Biopharmaceutical Co., Ltd. The company's stock resumed trading from the start of the market on October 31, 2024.

It is worth mentioning that just before the suspension of Ho-Oh Bo's stock, the company's stock price rose for four consecutive trading days, and on the last trading day before the suspension (October 23), the stock price rose by 7.41%.